Pml represses tumour progression through inhibition of mTOR

Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis

(2010) M D Lacher et al.   ONCOGENE

Therapeutic targeting of mTOR in tuberous sclerosis

(2009) Julian R. Sampson   BIOCHEMICAL SOCIETY TRANSACTIONS

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors

(2009) J. Huang et al.   CANCER RESEARCH

Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis

(2009) Cleo S. Bonnet et al.   HUMAN MOLECULAR GENETICS

Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1

(2009) Jing Zhou et al.   HUMAN MOLECULAR GENETICS

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

(2009) Kristen Pollizzi et al.   Molecular Cancer

The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition

(2008) M Shiono et al.   ONCOGENE